1. Confounding factors may explain the observed TB reduction
Many commenters argue that socioeconomic status, better healthcare access, or general health‑seeking behavior—not the drug itself—could drive the lower infection rates among GLP‑1 users.
- “I wonder if the likelihood that people taking a GLP-1 are probably better off financially, have a health care provider willing to spend on the drugs (and therefore probably a better medical system) … are the real reason there are fewer infections.” — master_crab
- “Although we adjus‑ ted for several available proxies of socioeconomic and lifestyle status, direct measures of income, insurance coverage, or out-of-pocket payment were not available … Residual confounding … cannot be excluded.” — yayamo
2. Mechanisms beyond weight loss are frequently proposed
Users suggest anti‑inflammatory effects, reduced adipose tissue, or improved glucose metabolism as plausible ways GLP‑1s could boost immunity.
- “They are also anti‑inflammatory, so it could be related to less systemic inflammation.” — ryanychants
- “The benefit is probably from the removal of fat … Fat plays a complex immunoregulatory role … the overall effect of fat … is negative.” — maxall4
- “Inam betting it's because of lowered inflammation allowing for stronger immune response.” — cromka
3. Cost and accessibility dominate practical concerns
A substantial part of the thread focuses on pricing, insurance coverage, and the availability of cheaper generic or compounded versions.
- “GLP‑1 receptor agonist medications typically cost between $149 and $350 per month for cash‑pay oral pills, and $900 to $1,400+ per month for list‑price injectables without insurance.” — drusepth (quoting typical range)
- “As low as $69/month through the compounding pharmacies.” — joshgachnang
- “I’m paying 300/m out of pocket. Really wish my insurance covered it.” — dawnerd